Carol Ashe

Carol Ashe is a seasoned professional in business development and legal operations, currently serving as the Chief Business Officer at the New York Genome Center since August 2014. In addition, Carol Ashe holds independent board director positions at Elicio Therapeutics and Aptose Biosciences, Inc. since August 2020 and August 2018, respectively. Previous roles include serving as Vice President of Corporate Development at Endo Pharmaceuticals and Partner at SR One (GlaxoSmithKline Venture Capital Group), along with various positions at GlaxoSmithKline from July 1989 to December 2008. Carol Ashe's educational background includes a Bachelor of Science in Biology from Penn State University and a Juris Doctor from the Villanova University Charles Widger School of Law.